James Bowman
@binder_finder_
Excited to share that a de novo designed miniprotein that myself, @bahl_lab, and @frankteets created during my post-doc is now in humans! The miniprotein is a Nectin-4 binding radiopharmaceutical being developed by Aktis Oncology.
Excited to share our new @ScienceMagazine paper! Led by postdocs Ruchao Peng and Xin Xu, we used cryo-EM/ET to reveal the influenza ribonucleoprotein complex structure and its strand-sliding mechanism for RNA synthesis, paving the way for new antivirals. science.org/doi/10.1126/sc…
Wow, wow, wow!!! The structure of human sweetness cell.com/cell/fulltext/…
I am so grateful to be back on the TED stage this week in Vancouver to share an update on our story. In the 6 years since my last TED talk, I left academia and founded AI Proteins. I can't wait to tell you about what we've been building. businesswire.com/news/home/2025…
Small proteins can be more complex than they look! We know proteins fluctuate between different conformations- but how much? How does it vary protein to protein? Can highly stable domains have low stability segments? @ajrferrari experimentally tested >5,000 domains to find out!
De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors 🚀 New preprint from David Baker!🚀 1. This paper introduces a computational and experimental approach for designing miniproteins targeting G protein-coupled receptors (GPCRs) with…
Dear Biotech Investment Community🙇 I just posted a deep-dive thread on $VKTX — analyzing their impressive PK profile and the science behind it. If you find it helpful, I’d be truly grateful for a RT or follow. Your support keeps me going, and I’ll keep sharing data-driven…
I initially thought that the extended half-life of Compound 23 was due to enhanced albumin binding— after all, attaching fatty acids to peptides is commonly intended to increase albumin affinity and prolong circulation time. In fact, Viking’s patent (WO2023044290) indicates they…
Scalable and cost-efficient custom gene library assembly from oligopools biorxiv.org/content/10.110… #biorxiv_synbio
Excited to share this work from the Garcia Lab out today in @NatureComms! We engineer "cytokine adaptors", molecular switches that simultaneously block a target cytokine while inducing local activation of alternative cytokine receptors. rdcu.be/ec7GS
Extremely clever new NGS tech from Roche 🧬 If it's hard to discriminate between nucleic acids accurately with a nanopore, why not synthesize a new polymer off a DNA template that is easier to sequence? It's an intuitively simple idea, but took *a ton* of creative nucleic acid…
CONFERENCES | On Feb 2025, @iibm_uc PhD student @afgrinen gave a fantastic talk on the design of novel PET-degrading enzymes using deep learning, in collaboration with @AI_Proteins, during the 2025 edition of Winter RosettaCon from @RosettaCommons in Boston
A socratic dialogue over the utility of DNA language models (Part 1 of 2) here's the link: owlposting.com/p/a-socratic-d… and here's a longpost of why i wrote this: i think the effort that went into Evo 2 is very cool and its clearly a very comprehensive paper but the excitement…
Site-saturation mutagenesis of 500 human protein domains | Nature nature.com/articles/s4158…
See Mireia Solà Colom @MireiaSol6, Head of Immunotherapeutics at @AI_Proteins, as she presents our latest progress on the design and optimization of immune cell engagers built from our de novo #miniproteins
for the folks who weren't able to join for @MireiaSol6's brilliant presentation last week to cap off our 2024 seminar series, you can check out the recording 👇 youtu.be/e6oZgGWjD_0
💫🌟🎯 NECTIN4 Amplification Predicts Enfortumab Vedotin Response in mUC🌟💫 @OncoAlert 🔬 Key finding: NECTIN4 amplification predicts a 96% objective response to Enfortumab Vedotin (EV) in metastatic urothelial cancer (mUC). 📈 Survival: NECTIN4 amplification reduces the risk…
You can read more about our exciting new collaboration with Bristol Myers Squibb in this coverage from Fierce Biotech fiercebiotech.com/biotech/bristo…
We've got some very exciting news to share! businesswire.com/news/home/2024… and here's a 🧵 about the journey from academia to @AI_Proteins
@AI_Proteins is excited to partner with @bmsnews to develop novel miniprotein-based therapeutics. This collaboration will leverage our cutting-edge AI-driven platform to design and optimize miniproteins with the potential to transform patient outcomes. businesswire.com/news/home/2024…
FT825/ONO-8250, a HER2 CAR-T cell therapy co-developed by Fate Therapeutics and ONO PHARMACEUTICAL and now in Phase 1 trials, incorporates advanced engineering techniques. The challenge in HER2 CAR-T development extends beyond merely applying CAR-T cell therapy to solid tumors;…
Excited to present a poster at #SITC24 @sitcancer on work led by @MireiaSol6. We will share data on miniprotein based immunotherapeutics that are functional in an animal model for acute myeloid leukemia. Check out the abstract here: jitc.bmj.com/content/12/Sup…
